(ETON) Eton Pharmaceuticals - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US29772L1089

ETON: Hormone Replacement, Acid Treatment, Amino Acid Therapy, Crisis Injector

Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company specializing in the development, acquisition, and commercialization of treatments for rare diseases. Its product portfolio includes ALKINDI SPRINKLE, the first and only FDA-approved sprinkle formulation for hydrocortisone, designed for pediatric adrenocortical insufficiency; Carglumic Acid, an orphan drug for N-acetylglutamate synthase deficiency; Betaine Anhydrous, addressing homocystinuria; and Nitisinone, a life-long treatment for hereditary tyrosinemia type 1. The company also markets Zeneo, a hydrocortisone autoinjector for acute adrenal crisis. Since its inception in 2017, Eton has focused on improving patient access to critical therapies through its targeted pipeline and commercial strategy.

From a stock perspective, ETON is trading at $15.70 with a 20-day average volume of 286,603 shares. The stock has shown upward momentum, with a 20-day SMA of 16.27 and a 50-day SMA of 14.89, reflecting recent strength. The 200-day SMA of 8.20 highlights significant growth over the past year. With an ATR of 1.08, volatility remains moderate. Fundamentally, ETON has a market cap of $236.92M, a forward P/E of 17.92, and a P/S ratio of 10.90, indicating a rich valuation. The negative RoE of -34.30% reflects current losses but may improve as revenues scale.

3-Month Forecast: Based on and , ETON is expected to trade in a range of $14 to $17 over the next quarter. The stocks upward trend, supported by its 20-day and 50-day SMAs, suggests potential for further gains. However, the high P/S ratio and negative earnings may lead to volatility. Upside could materialize if the company demonstrates progress in its pipeline or reports better-than-expected revenues, while downside risks may emerge if growth slows or expenses rise unexpectedly.

Additional Sources for ETON Stock

ETON Stock Overview

Market Cap in USD 237m
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
GiC Sub-Industry Pharmaceuticals
IPO / Inception 2018-11-13

ETON Stock Ratings

Growth 5y 48.7%
Fundamental -28.1%
Dividend 0.0%
Rel. Strength Industry 246
Analysts 4.67/5
Fair Price Momentum 14.31 USD
Fair Price DCF 0.63 USD

ETON Dividends

No Dividends Paid

ETON Growth Ratios

Growth Correlation 3m 59.1%
Growth Correlation 12m 90.7%
Growth Correlation 5y -18.4%
CAGR 5y 38.04%
CAGR/Max DD 5y 0.48
Sharpe Ratio 12m 1.38
Alpha 237.34
Beta 1.20
Volatility 72.74%
Current Volume 191k
Average Volume 20d 209.8k
What is the price of ETON stocks?
As of March 15, 2025, the stock is trading at USD 15.58 with a total of 191,027 shares traded.
Over the past week, the price has changed by +6.79%, over one month by -5.09%, over three months by +22.29% and over the past year by +249.33%.
Is Eton Pharmaceuticals a good stock to buy?
Probably not. Based on ValueRay Fundamental Analyses, Eton Pharmaceuticals (NASDAQ:ETON) is currently (March 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -28.05 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ETON as of March 2025 is 14.31. This means that ETON is currently overvalued and has a potential downside of -8.15%.
Is ETON a buy, sell or hold?
Eton Pharmaceuticals has received a consensus analysts rating of 4.67. Therefor, it is recommend to buy ETON.
  • Strong Buy: 2
  • Buy: 1
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0
What are the forecast for ETON stock price target?
According to ValueRays Forecast Model, ETON Eton Pharmaceuticals will be worth about 16.1 in March 2026. The stock is currently trading at 15.58. This means that the stock has a potential upside of +3.47%.
Issuer Forecast Upside
Wallstreet Target Price 13 -16.6%
Analysts Target Price 13 -16.6%
ValueRay Target Price 16.1 3.5%